Selected article for: "cell receptor and family virus"
Author: Hung, Yuan-Pin; Lee, Ching-Chi; Lee, Jen-Chieh; Tsai, Pei-Jane; Ko, Wen-Chien
Title: Gut Dysbiosis during COVID-19 and Potential Effect of Probiotics
  • Cord-id: jhxds8x6
  • Document date: 2021_7_28
    • ID: jhxds8x6
    Snippet: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an RNA virus of the family Coronaviridae, causes coronavirus disease 2019 (COVID-19), an influenza-like disease that chiefly infects the lungs through respiratory transmission. The spike protein of SARS-CoV-2, a transmembrane protein in its outer portion, targets angiotensin-converting enzyme 2 (ACE2) as the binding receptor for the cell entry. As ACE2 is highly expressed in the gut and pulmonary tissues, SARS-CoV-2 infections frequen
    Document: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an RNA virus of the family Coronaviridae, causes coronavirus disease 2019 (COVID-19), an influenza-like disease that chiefly infects the lungs through respiratory transmission. The spike protein of SARS-CoV-2, a transmembrane protein in its outer portion, targets angiotensin-converting enzyme 2 (ACE2) as the binding receptor for the cell entry. As ACE2 is highly expressed in the gut and pulmonary tissues, SARS-CoV-2 infections frequently result in gastrointestinal inflammation, with presentations ordinarily ranging from intestinal cramps to complications with intestinal perforations. However, the evidence detailing successful therapy for gastrointestinal involvement in COVID-19 patients is currently limited. A significant change in fecal microbiomes, namely dysbiosis, was characterized by the enrichment of opportunistic pathogens and the depletion of beneficial commensals and their crucial association to COVID-19 severity has been evidenced. Oral probiotics had been evidenced to improve gut health in achieving homeostasis by exhibiting their antiviral effects via the gut–lung axis. Although numerous commercial probiotics have been effective against coronavirus, their efficacies in treating COVID-19 patients remain debated. In ClinicalTrials.gov, 19 clinical trials regarding the dietary supplement of probiotics, in terms of Lactobacillus and mixtures of Bifidobacteria and Lactobacillus, for treating COVID-19 cases are ongoing. Accordingly, the preventive or therapeutic role of probiotics for COVID-19 patients can be elucidated in the near future.

    Search related documents:
    Co phrase search for related documents
    • acid produce and adaptive innate: 1
    • acid produce and lymph node: 1
    • activation inflammasome and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8
    • activation inflammasome and local systemic: 1
    • activation inflammasome and lymph node: 1
    • activation inflammasome and macrophage inflammatory: 1, 2, 3
    • active sars infection and adaptive innate: 1
    • active sars infection and adjuvant therapy: 1
    • active sars infection and local systemic: 1
    • adaptive innate and adjuvant therapy: 1, 2
    • adaptive innate and local systemic: 1, 2, 3, 4, 5, 6, 7
    • adaptive innate and lymph node: 1, 2, 3, 4, 5, 6, 7, 8
    • adaptive innate and macrophage inflammatory: 1, 2, 3, 4, 5
    • adjuvant therapy and local systemic: 1
    • adjuvant therapy and lymph node: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • adjuvant therapy and macrophage inflammatory: 1
    • local systemic and lymph node: 1, 2, 3, 4, 5, 6, 7
    • local systemic and macrophage inflammatory: 1, 2, 3